Generate Biomedicines (GENB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Generate Biomedicines (GENB) is Moderate Underperform.

The composite score behind that read is -0.30, weighing +0.75 of bullish evidence against -0.37 bearish.

Generate Biomedicines last closed at $13.91, +1.61% on the session.

Against the IVW growth benchmark the position is +0.69% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

16 graded predictions for GENB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Generate Biomedicines is classified under Health Care / Biotechnology, with a market capitalisation of $1.76B.

StockMap tracks Generate Biomedicines as the 97th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Generate Biomedicines ranks 253rd of 344 in the group, against a group median of -0.21.